Literature DB >> 25769380

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

Antonin Levy1, David Azria2, Jean-Pierre Pignon3, Anne Delarochefordiere4, Isabelle Martel-Lafay5, Emmanuel Rio6, David Malka7, Thierry Conroy8, Laurent Miglianico9, Yves Becouarn10, Katty Malekzadeh3, Julie Leclercq3, Beata Juzyna8, Patrick Ezra11, Claire Lemanski2, Eric Deutsch12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25769380     DOI： 10.1016/j.radonc.2015.02.008

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  6 in total

1.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Authors:  Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

Review 2.  Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).

Authors:  Eleonor Rivin Del Campo; Oscar Matzinger; Karin Haustermans; Didier Peiffert; Robert Glynne-Jones; Kathryn A Winter; Andre A Konski; Jaffer A Ajani; Jean-François Bosset; Jean-Michel Hannoun-Levi; Marc Puyraveau; A Bapsi Chakravarthy; Helen Meadows; John Northover; Laurence Collette; Melissa Christiaens; Philippe Maingon
Journal:  Eur J Cancer       Date:  2019-09-28       Impact factor: 9.162

3.  Molecular characterization of squamous cell carcinoma of the anal canal.

Authors:  Mohamed E Salem; Benjamin A Weinberg; Samantha A Armstrong; Rita Malley; Hongkun Wang; Heinz-Josef Lenz; David Arguello; Wafik S El-Deiry; Joanne Xiu; Zoran Gatalica; Jimmy J Hwang; Philip A Philip; Anthony F Shields; John L Marshall
Journal:  J Gastrointest Oncol       Date:  2021-10

Review 4.  Squamous-cell carcinoma of the anus: progress in radiotherapy treatment.

Authors:  Rob Glynne-Jones; David Tan; Robert Hughes; Peter Hoskin
Journal:  Nat Rev Clin Oncol       Date:  2016-01-27       Impact factor: 66.675

Review 5.  Background and Current Treatment of Squamous Cell Carcinoma of the Anus.

Authors:  Rob Glynne-Jones; Waqar Saleem; Mark Harrison; Suzy Mawdsley; Marcia Hall
Journal:  Oncol Ther       Date:  2016-08-01

6.  VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).

Authors:  Jaime Feliu; Rocio Garcia-Carbonero; Jaume Capdevila; Inmaculada Guasch; Vicente Alonso-Orduna; Carlos Lopez; Pilar Garcia-Alfonso; Carmen Castanon; Isabel Sevilla; Laura Cerezo; Carles Conill; Begona Quintana-Angel; Maria E Sanchez; Ismael Ghanem; Marta Martin-Richard; Miriam Lopez-Gomez; Ana Leon; Monica Caro; Teresa Fernandez; Joan Maurel
Journal:  Cancer Med       Date:  2019-12-18       Impact factor: 4.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.